摘要
目的:对鲜竹沥的化学成分进行研究,并对获得的单体成分进行体外抗炎活性评价。方法:应用正相和反相硅胶柱色谱、凝胶色谱以及制备液相色谱进行制备,并根据核磁、紫外、红外、圆二色谱等试验数据,鉴定化合物结构。结果:共分离鉴定得到4个化合物,分别为:1、(7S,8S)-5'-甲氧基-2,3,4,9-四羟基-3':7,4':8-二环氧新木脂素-1′-羧酸甲酯;2、紫菀苷A;3、(+)-ovafolinin B-9′-O-β-D-glucopyranoside;4、苯丙酮4′-O-茜黄樱草糖甙。结论:化合物1是新化合物,体外活性检测表明,其具有抗炎活性,能剂量依赖性地抑制LPS诱导的RAW264.7细胞NO、TNF-α和IL-6的释放化合物;2~4是首次从鲜竹沥中分离得到的化合物。
Objective:To study the chemical constituents and anti-inflammatory activity of Xianzhuli.Methods:The compounds were prepared by normal-phase and reversed-phase Silica Gel Column Chromatography,Gel Chromatography and preparative liquid chromatography,and their structures were identified by NMR,UV,IR and CD Spectra.Results:Four compounds were isolated from Xianzhuli and elucidated as 1.(7S,8S)-5'-methoxyl-2,3,4,9-dihydroxy-3':7,4':8-diepoxyneolignan-1'-carboxylic acid methyl ester;2.asterbatanoside A;3.(+)-ovafolinin B-9′-O-β-D-glucopyranoside;and4.propiophenone 4′-O-primeveroside.Conclusion:Compound 1 was a new compound named Xianzhuli A,Xianzhuli A exhibited anti-inflammatory activity in vitro.which inhibited NO,TNF-αand IL-6 production in RAW 264.7 cells stimulated with LPS in a dose-dependent manner,and compounds 2-4 were obtained from Xianzhuli for the first time.
作者
谭洋
刘良玉
游媛
姚金龙
林凯鹏
付辉政
罗跃华
TAN Yang;LIU Liangyu;YOU Yuan;YAO Jinlong;LIN Kaipeng;FU Huizheng;LUO Yuehua(China State Institute of Pharmaceutical Industry,Shanghai 201203,China;Jiangxi Provincial Institute for Drug Control,NMPA Key Laboratory of Quality Evaluation of Traditional Chinese Patent Medicine,Jiangxi Provincial Engineering Research Center for Drug and Medical Device Quality,Nanchang Jiangxi 330029,China;Jiangxi Provincial Drug Inspector Center,Nanchang Jiangxi 330029,China)
出处
《药品评价》
CAS
2020年第23期12-15,共4页
Drug Evaluation
基金
江西省重点研发计划项目(20171BBG70103)
国家药典委员会药品标准提高项目(2019Z085)。
